Upside – $KOD +60% (pivotal Phase 3 DAYBREAK wet-AMD trial met its primary noninferiority endpoints, with most patients reaching a 24-week dosing interval) – $ARAY +39% (agrees to explore integrating Samsung NeuroLogica volumetric imaging technology with the CyberKnife platform) – $MEDS +28% (launches a GLP-1 care app offering telehealth consultations and access to branded medications) …
Read in context ›Freeport-McMoRan Stock (FCX)
Track Freeport-McMoRan stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
FCX
Freeport-McMoRan
basicmaterials
At close
$73.69
▲ +2.55 (+3.58%)
Oct 9, 4:00 PM ET
After-hours
$73.65
▼ -0.04 (-0.05%)
Oct 9, 7:59 PM ET
Market Cap
$102.16B
P/E Ratio
36.3x
1Y Return
+71.97%
EPS (TTM)
$2.03
Read the latest TheStreet Pro articles mentioning Freeport-McMoRan, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
43 articlesDaily Diary Mentions
1 mentionUpside, Downside Movers in the Morning